


PHARMACEUTICAL 2020











PHARMACEUTICAL 2020



ENANTA PHARMACEUTICALS INC Rank 13 of 362



The relative strengths and weaknesses of ENANTA PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENANTA PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 393% points. The greatest weakness of ENANTA PHARMACEUTICALS INC is the variable Research and Development, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 270%, being 573% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	401,848
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,609
Liabilities, Non-Current	3,100
Other Assets	77,054
Other Compr. Net Income	544
Other Expenses	-826
Other Liabilities	1,628
Other Net Income	8,819
Property and Equipment	10,927
Research and Development	142,213
Revenues	205,197
Selling, General and Administrative Expense	26,246

Output Variable	Value in 1000 USD
Assets	489,829
Liabilities	27,337
Expenses	167,633
Stockholders Equity	462,492
Net Income	46,383
Comprehensive Net Income	46,655
Economic Capital Ratio	270%

